

Contact:

Peter Hebert
Lux Research, Inc.
646-723-0702
peter.hebert@luxresearchinc.com

LUX RESEARCH ANNOUNCES FIRST QUARTER UPDATE OF LUX NANOTECH INDEX™

New York, NY – April 3, 2006 – Lux Research, the world's leading nanotechnology research and advisory firm, today announced its quarterly update to the Lux Nanotech Index™. The Index serves as a benchmark for the value that markets ascribe to emerging nanotechnology and forms the basis of the \$93 million PowerShares Lux Nanotech Portfolio (AMEX:PXN), the first nanotechnology exchange-traded fund (ETF).

The components of the Lux Nanotech Index™ are split into two groups: 1) nanotech specialists – small and mid-sized companies that focus specifically on developing or funding emerging nanotechnology applications, and 2) end-use incumbents – large companies that are applying nanotechnology to existing product lines. Nanotech specialists account for 75% of the modified equal-dollar-weighted index; end-use incumbents account for 25%.

This update replaces Westaim with NUCRYST Pharmaceuticals among the nanotech specialists. NUCRYST, which develops therapeutic applications of silver nanoparticles, was a business unit of Westaim before it was spun off in a late December 2005 IPO; with the spinoff, Westaim's nanotech commercialization activities have been divested. "The Acticoat antimicrobial bandages that NUCRYST developed with partner Smith & Nephew form a great example of how nanotechnology is changing products and shifting market shares today," said Lux Research President and Director of Research Matthew M. Nordan.

The PowerShares Lux Nanotech Portfolio, which is based on the Index, is up 19.90% since its introduction in October 2005 and now has more than \$93 million in assets under management. The Lux Nanotech Index™ is intended to be representative, and is not specifically designed to outperform the Nasdaq or other indices.

The components of the Lux Nanotech Index™ are:

Nanotech specialists

Accelrys (ACCL)
Altair Nanotechnologies (ALTI)
American Pharmaceutical Partners (APPX)
Arrowhead Research (ARWR)
Biosante Pharmaceuticals (BPA)
Elan (ELN)
FEI Company (FEIC)
Flamel Technologies (FLML)
Headwaters (HW)
Immunicon (IMMC)
Nanophase Technologies (NANX)
NUCRYST Pharmaceuticals (NCST)
NVE Corporation (NVEC)
Cambridge Display Technology (OLED)
Symyx Technologies (SMMX)
Harris & Harris Group (TINY)
Veeco Instruments (VECO)

End-use incumbents

Air Products & Chemicals (APD)

BASF (BF)
E.I. Du Pont de Nemours & Company (DD)
General Electric (GE)
Hewlett-Packard (HPQ)
Intel (INTC)
International Business Machines (IBM)
3M (MMM)
Toyota (TM)

Full details on the Lux Nanotech Index™ are available at www.luxresearchinc.com/luxni.html.

About Lux Research:

Lux Research is the world's leading nanotechnology research and advisory firm. We help our clients make better decisions to profit from nanoscale science and technology, tapping into our analysts' unique expertise and unrivaled network. Our clients include top decision makers at large corporations, portfolio managers and analysts at leading financial institutions, CEOs of the most innovative start-ups, and visionary public policy makers. Visit www.luxresearchinc.com for more information.

###